Premium
When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours?
Author(s) -
Singh Ospiykky,
Maraka Spyridoula,
Montori Victor,
Thompson Geoffrey B.,
Young William F.
Publication year - 2016
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12972
Subject(s) - multiple endocrine neoplasia , carcinoid tumour , medicine , endocrine system , endocrinology , multiple endocrine neoplasia type 2 , neuroendocrine tumour , biology , hormone , mutation , germline mutation , biochemistry , gene
Summary Patients with multiple endocrine neoplasia type 1 ( MEN 1) are commonly evaluated for clinical manifestations of this syndrome with the rationale that early diagnosis and adequate treatment will result in improved survival and quality of life. Thymic and bronchial carcinoid tumours are uncommon but important manifestations of MEN 1. Current practice guidelines recommend evaluation with computed tomography or magnetic resonance imaging scan of the chest every 1–2 years to detect these neoplasms. However, the certainty that patients will be better off (increased survival or quality of life) as a result of this case detection strategy is based on evidence at moderate–high risk of bias that yields only imprecise results of indirect relevance to these patients. In order to improve the care that patients with MEN 1 receive, co‐ordinated efforts from different stakeholders are required so that large, prospective, multicentre studies evaluating patient important outcomes are carried out.